This is the second antigen test the FDA has authorized for the detection of SARS-CoV-2 antigens.
This test is authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 for high, moderate, or waived complexity testing, meaning it can be used in patient care settings operating under a CLIA certificate of Waiver, certificate of Compliance, or certificate of Accreditation.
Emergency use of this test is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.
The FDA, an agency within the US Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project